William D Figg1, Cindy H Chau2, Douglas K Price2, Cathee Till3, Phyllis J Goodman3, Yonggon Cho4, Marileila Varella-Garcia5, Juergen K V Reichardt6, Catherine M Tangen3, Robin J Leach7, Adrie van Bokhoven5, Ian M Thompson7, M Scott Lucia5. 1. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Electronic address: figgw@helix.nih.gov. 2. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. 3. SWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Chonbuk National University Medical School, Jeonju, South Korea. 5. Department of Pathology, University of Colorado Denver School of Medicine, Aurora, CO. 6. School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland, Australia. 7. Department of Urology and Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Abstract
OBJECTIVE: To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. METHODS: This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. RESULTS: There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. CONCLUSION: Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer. Published by Elsevier Inc.
OBJECTIVE: To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. METHODS: This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. RESULTS: There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. CONCLUSION: Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer. Published by Elsevier Inc.
Authors: Elizabeth A Platz; Michael F Leitzmann; Nader Rifai; Philip W Kantoff; Yen-Ching Chen; Meir J Stampfer; Walter C Willett; Edward Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-05 Impact factor: 4.254
Authors: Matthew L Freedman; Celeste L Pearce; Kathryn L Penney; Joel N Hirschhorn; Laurence N Kolonel; Brian E Henderson; David Altshuler Journal: Am J Hum Genet Date: 2004-11-29 Impact factor: 11.025
Authors: P Feigl; B Blumenstein; I Thompson; J Crowley; M Wolf; B S Kramer; C A Coltman; O W Brawley; L G Ford Journal: Control Clin Trials Date: 1995-06
Authors: Grant Buchanan; Miao Yang; Albert Cheong; Jonathan M Harris; Ryan A Irvine; Paul F Lambert; Nicole L Moore; Michael Raynor; Petra J Neufing; Gerhard A Coetzee; Wayne D Tilley Journal: Hum Mol Genet Date: 2004-06-15 Impact factor: 6.150
Authors: Pierre P Massion; Yong Zou; Hasmet Uner; Porntip Kiatsimkul; Holly J Wolf; Anna E Baron; Tim Byers; Steinn Jonsson; Stephen Lam; Fred R Hirsch; York E Miller; Wilbur A Franklin; Marileila Varella-Garcia Journal: PLoS One Date: 2009-06-09 Impact factor: 3.240
Authors: Rebecca E Graff; Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Kathryn L Penney; Kathryn M Wilson; Sarah C Markt; Claire H Pernar; Amparo G Gonzalez-Feliciano; Mingyang Song; Rosina T Lis; Daniel R Schmidt; Matthew G Vander Heiden; Michelangelo Fiorentino; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-22 Impact factor: 4.254
Authors: Rebecca E Graff; Allison Meisner; Thomas U Ahearn; Michelangelo Fiorentino; Massimo Loda; Edward L Giovannucci; Lorelei A Mucci; Andreas Pettersson Journal: Br J Cancer Date: 2016-03-17 Impact factor: 7.640